Pharmena S.A.
PHR.WA · WSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | PLN 407 | PLN 386 | PLN 393 | PLN 88 |
| % Growth | 5.4% | -1.8% | 346.6% | – |
| Cost of Goods Sold | PLN 62 | PLN 1,063 | PLN 92 | PLN 13 |
| Gross Profit | PLN 345 | -PLN 677 | PLN 301 | PLN 75 |
| % Margin | 84.8% | -175.4% | 76.6% | 85.2% |
| R&D Expenses | PLN 0 | PLN 0 | PLN 0 | PLN 10 |
| G&A Expenses | PLN 711 | PLN 656 | PLN 504 | PLN 714 |
| SG&A Expenses | PLN 1,132 | PLN 1,240 | PLN 953 | PLN 983 |
| Sales & Mktg Exp. | PLN 421 | PLN 584 | PLN 449 | PLN 269 |
| Other Operating Expenses | PLN 0 | -PLN 1,041 | PLN 14 | -PLN 189 |
| Operating Expenses | PLN 1,132 | PLN 199 | PLN 967 | PLN 804 |
| Operating Income | -PLN 787 | -PLN 876 | -PLN 666 | -PLN 729 |
| % Margin | -193.4% | -226.9% | -169.5% | -828.4% |
| Other Income/Exp. Net | PLN 98 | PLN 168 | PLN 187 | PLN 142 |
| Pre-Tax Income | -PLN 689 | -PLN 708 | -PLN 479 | -PLN 587 |
| Tax Expense | PLN 1 | PLN 8 | PLN 10 | -PLN 471 |
| Net Income | -PLN 690 | -PLN 700 | -PLN 489 | -PLN 118 |
| % Margin | -169.5% | -181.3% | -124.4% | -134.1% |
| EPS | 0 | -0.063 | -0.044 | -0.011 |
| % Growth | 100% | -43.1% | -314.2% | – |
| EPS Diluted | 0 | -0.07 | -0.044 | -0.011 |
| Weighted Avg Shares Out | 0 | 10,000 | 11,138 | 11,138 |
| Weighted Avg Shares Out Dil | 0 | 11,138 | 11,138 | 11,138 |
| Supplemental Information | – | – | – | – |
| Interest Income | PLN 107 | PLN 168 | PLN 194 | PLN 144 |
| Interest Expense | PLN 9 | PLN 0 | PLN 7 | PLN 0 |
| Depreciation & Amortization | PLN 29 | PLN 30 | PLN 31 | PLN 5 |
| EBITDA | -PLN 651 | -PLN 846 | -PLN 441 | -PLN 944 |
| % Margin | -160% | -219.2% | -112.2% | -1,072.4% |